XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer Nov 04, 2021 7:40am EDT
XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events Nov 04, 2021 7:30am EDT
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Sep 22, 2021 7:30am EDT
XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events Aug 05, 2021 7:30am EDT
U.S. Food and Drug Administration has Granted Orphan Drug Designation to XOMA’s Licensed anti-TGFβ Asset NIS793 Jul 28, 2021 7:30am EDT
